Literature DB >> 19527736

Deleterious effects of silymarin on the expression of genes controlling endothelial nitric oxide synthase activity in carbon tetrachloride-treated rat livers.

Yong Kyun Cho1, Jung Won Yun, Jung Ho Park, Hong Joo Kim, Dong Il Park, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Wook Jin, Yong-Hyun Kwon, Mi-Kyung Shin, Tae Moo Yoo, Ju-Hee Kang, Chang-Shin Park.   

Abstract

AIMS: Defects in intrahepatic nitric oxide (NO) are attributed to reduced blood flow due to portal hypertension caused by diminished endothelial NO synthase (eNOS) activity. The aim of this study is to identify the therapeutic effects of silymarin on eNOS/NO-related enzymes and hepatic enzymes in carbon tetrachloride (CCl4)-induced cirrhotic rats. MAIN
METHODS: CCl4 treated for 12 weeks was discontinued and then administrated with silymarin daily for 4 weeks. Collagen concentrations were determined by measuring hydroxyproline content. Serum was assayed for hepatic enzymes like alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) activities. NOS activities were measured by oxyhemoglobin oxidation assay, and levels of enzyme expression and phosphorylation were detected by Western-blot analyses. KEY
FINDINGS: Silymarin treatment restored the values for collagen content and ALT and ALP activities when compared to the values with spontaneous resolution following discontinuation of CCl4. CCl4 treatment highly increased eNOS expression and NOS activity in livers, but the phosphorylation was markedly decreased. Silymarin decreased significantly eNOS expression and activity. Expression and/or phosphorylation of enzymes activating eNOS were unchanged (Akt and AMPK) or decreased (PKA) by silymarin. Especially, the expression of caveolin-1, an inhibitor of eNOS was unchanged by CCl4, but its phosphorylation was significantly increased. However, silymarin markedly increased caveolin-1 expression but decreased its phosphorylation to expression. SIGNIFICANCE: These results suggest that chronic silymarin treatment can improve cirrhosis-induced liver enzyme activities and fibrosis, but may aggravate the hemodynamic eNOS activity, particularly by decreasing eNOS expression and increasing caveolin-1 expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19527736     DOI: 10.1016/j.lfs.2009.06.001

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial.

Authors:  N D Freedman; T M Curto; C Morishima; L B Seeff; Z D Goodman; E C Wright; R Sinha; J E Everhart
Journal:  Aliment Pharmacol Ther       Date:  2010-11-02       Impact factor: 8.171

2.  Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis.

Authors:  Naglaa M El-Lakkany; Olfat A Hammam; Walaa H El-Maadawy; Afkar A Badawy; Afaf A Ain-Shoka; Fatma A Ebeid
Journal:  Parasit Vectors       Date:  2012-01-11       Impact factor: 3.876

3.  AMPK: a novel target for treating hepatic fibrosis.

Authors:  Zhenxing Liang; Tian Li; Shuai Jiang; Jing Xu; Wencheng Di; Zhi Yang; Wei Hu; Yang Yang
Journal:  Oncotarget       Date:  2017-07-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.